Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:42:27.599Z.
Calculation as of: 2026-10-06T20:42:27.599Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bddae1a009f0b40e7fb659cb125a310776fd64778f9839bff19075a224db575c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$169.53M
Price/FCF Ratio
N/A
TTM Avg
81.50
3Y Avg
61.57
5Y Avg
61.57
Market Cap
$159.80M
Price/FCF Ratio
N/A
TTM Avg
78.89
3Y Avg
78.89
5Y Avg
78.89
Market Cap
$171.13M
Price/FCF Ratio
N/A
TTM Avg
396.65
3Y Avg
396.65
5Y Avg
396.65
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nkarta, Inc. (NKTX) | $165.27M | N/A | N/A | N/A | N/A |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 9.01 | 14.25 | 49.54 | 46.02 |
| Cue Biopharma, Inc. (CUE)vs › | $168.10M | N/A | N/A | N/A | N/A |
| Quanterix Corporation (QTRX)vs › | $162.04M | N/A | N/A | N/A | N/A |
| MediWound Ltd. (MDWD)vs › | $168.92M | N/A | 8.04 | 8.04 | 8.04 |
| Journey Medical Corporation (DERM)vs › | $169.53M | N/A | 81.50 | 61.57 | 61.57 |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | N/A | 78.89 | 78.89 | 78.89 |
| PepGen Inc. (PEPG)vs › | $159.78M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | N/A | 396.65 | 396.65 | 396.65 |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | N/A | 177.92 | 1258.54 | 1258.54 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
